Overview

Lurbinectedin in FET-Fused Tumors

Status:
Recruiting

Trial end date:
2028-07-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Children's Hospital of Philadelphia

Collaborators:

Jazz Pharmaceuticals
Stand Up To Cancer